Neil McFarlane
Algemeen Directeur bij ZEVRA THERAPEUTICS, INC.
Vermogen: 2 M $ op 30-04-2024
Actieve functies van Neil McFarlane
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Directeur/Bestuurslid | 06-04-2022 | - |
| Independent Dir/Board Member | 06-04-2022 | - | |
| ZEVRA THERAPEUTICS, INC. | Directeur/Bestuurslid | 10-10-2023 | - |
| Algemeen Directeur | 10-10-2023 | - | |
| President | 10-10-2023 | - |
Loopbaan van Neil McFarlane
Eerdere bekende functies van Neil McFarlane
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Adamas Pharmaceuticals, Inc. | Directeur/Bestuurslid | 01-09-2019 | 01-11-2021 |
| Algemeen Directeur | 01-09-2019 | 01-11-2021 | |
| ADAMAS PHARMACEUTICALS, INC. | Algemeen Directeur | 16-09-2019 | 01-01-2021 |
| TRAVERE THERAPEUTICS, INC. | Operationeel Directeur | 15-08-2016 | 31-05-2019 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01-01-2011 | 01-01-2016 |
Opleiding van Neil McFarlane
| University of Florida | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 8 |
Operationeel
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Chief Operating Officer | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 2 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
| Adamas Pharmaceuticals, Inc. |
- Beurs
- Insiders
- Neil McFarlane
- Ervaring